This is a Validated Antibody Database (VAD) review about human MDM4, based on 28 published articles (read how Labome selects the articles), using MDM4 antibody in all methods. It is aimed to help Labome visitors find the most suited MDM4 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
MDM4 synonym: HDMX; MDMX; MRP1; protein Mdm4; MDM4 protein variant G; MDM4 protein variant Y; MDM4-related protein 1; Mdm4 p53 binding protein homolog; double minute 4, human homolog of; p53-binding protein; mdm2-like p53-binding protein; protein Mdmx

Bethyl
rabbit polyclonal
  • western blot; human; 1:500; loading ...; fig 2
In order to use polo-like kinase 1 inhibitors for a rationally designed chemotherapy protocols to treat patients with metastasized retinoblastoma, Bethyl MDM4 antibody (Bethyl Laboratories, a300-287a) was used in western blot on human samples at 1:500 (fig 2). Clin Exp Ophthalmol (2017) ncbi
rabbit polyclonal
  • immunoprecipitation; human; fig 6
  • western blot; human; 1:10,000; fig 6
Bethyl MDM4 antibody (Bethyl, A300-287A) was used in immunoprecipitation on human samples (fig 6) and in western blot on human samples at 1:10,000 (fig 6). Oncotarget (2016) ncbi
rabbit polyclonal
  • western blot; human; loading ...; fig 3d
Bethyl MDM4 antibody (Bethyl laboratories, A300287A-2) was used in western blot on human samples (fig 3d). Mol Cancer Ther (2016) ncbi
rabbit polyclonal
  • western blot; human; fig 2
In order to examine the relationship between PML IV and ARF, Bethyl MDM4 antibody (Bethyl, A300-287A) was used in western blot on human samples (fig 2). Proc Natl Acad Sci U S A (2015) ncbi
rabbit polyclonal
  • immunohistochemistry; human; fig 1a
Bethyl MDM4 antibody (Bethyl Laboratories, A300 287A) was used in immunohistochemistry on human samples (fig 1a). Cell Death Dis (2015) ncbi
rabbit polyclonal
  • western blot; human; 1:500; fig 2
Bethyl MDM4 antibody (Bethyl Laboratories, A300-287A) was used in western blot on human samples at 1:500 (fig 2). Sci Rep (2015) ncbi
rabbit polyclonal
  • western blot; human; 1:3000; fig 3
Bethyl MDM4 antibody (Bethyl Labs, A300-287A) was used in western blot on human samples at 1:3000 (fig 3). Endocr Relat Cancer (2015) ncbi
rabbit polyclonal
  • western blot; human; 1 ug/ml
Bethyl MDM4 antibody (Bethyl, A300-287A) was used in western blot on human samples at 1 ug/ml. PLoS ONE (2014) ncbi
rabbit polyclonal
  • western blot; human; 1:1000
Bethyl MDM4 antibody (Bethyl Laboratories, A300-287A) was used in western blot on human samples at 1:1000. Biochim Biophys Acta (2014) ncbi
rabbit polyclonal
  • western blot; human
Bethyl MDM4 antibody (Bethyl Laboratories, A300-287A) was used in western blot on human samples . Cancer Res (2011) ncbi
Santa Cruz Biotechnology
mouse monoclonal (G-10)
  • western blot; human; 1:500; loading ...; fig 3b
Santa Cruz Biotechnology MDM4 antibody (Santa Cruz Biotechnology, sc-74467) was used in western blot on human samples at 1:500 (fig 3b). Nat Commun (2018) ncbi
mouse monoclonal (D-4)
  • western blot; mouse; 1:200; fig s4
Santa Cruz Biotechnology MDM4 antibody (Santa Cruz, sc-74468) was used in western blot on mouse samples at 1:200 (fig s4). Nat Commun (2016) ncbi
mouse monoclonal (A-11)
  • western blot; human; loading ...; fig 3c
Santa Cruz Biotechnology MDM4 antibody (Santa Cruz, sc-374147) was used in western blot on human samples (fig 3c). Oncogene (2016) ncbi
LifeSpan Biosciences
mouse monoclonal (2D10F4)
  • immunocytochemistry; human; loading ...; fig 3e
  • western blot; human; loading ...; fig 2a
LifeSpan Biosciences MDM4 antibody (LifeSpan, 2D10F4) was used in immunocytochemistry on human samples (fig 3e) and in western blot on human samples (fig 2a). Oncogene (2017) ncbi
Abcam
mouse monoclonal (15)
  • immunohistochemistry - paraffin section; mouse; fig s2
  • western blot; mouse; fig 5
Abcam MDM4 antibody (Abcam, ab122926) was used in immunohistochemistry - paraffin section on mouse samples (fig s2) and in western blot on mouse samples (fig 5). Oncotarget (2015) ncbi
rabbit polyclonal
  • western blot; human
Abcam MDM4 antibody (Abcam, ab16058) was used in western blot on human samples . Oncotarget (2014) ncbi
Proteintech Group
rabbit polyclonal
  • western blot; human
Proteintech Group MDM4 antibody (Proteintech, 17914-1-AP) was used in western blot on human samples . Cancer Res (2014) ncbi
EMD Millipore
mouse monoclonal (QCRL-1)
  • other; human; 1:50; fig 3b
EMD Millipore MDM4 antibody (Millipore, MAB4100) was used in other on human samples at 1:50 (fig 3b). PLoS ONE (2017) ncbi
mouse monoclonal (8C6)
  • western blot; human; 1:300; loading ...; fig 1b
In order to elucidate the contribution of MDM2 expression to retinoblastoma tumorigenesis, EMD Millipore MDM4 antibody (Millipore, 04-1555) was used in western blot on human samples at 1:300 (fig 1b). Oncogene (2017) ncbi
mouse monoclonal (QCRL-1)
  • immunocytochemistry; human; 1:25; fig 2h
In order to examine trafficking of cancer-targeting alkylphosphocholine analogues across the blood brain barrier, EMD Millipore MDM4 antibody (Millipore, QCRL-1) was used in immunocytochemistry on human samples at 1:25 (fig 2h). Mol Pharm (2016) ncbi
mouse monoclonal (8C6)
  • western blot; human; loading ...; fig s8
EMD Millipore MDM4 antibody (Millipore, 8C6) was used in western blot on human samples (fig s8). Science (2016) ncbi
mouse monoclonal (8C6)
  • immunocytochemistry; human; 1:25; fig 2
EMD Millipore MDM4 antibody (Millipore, 04-1555) was used in immunocytochemistry on human samples at 1:25 (fig 2). Oncotarget (2016) ncbi
mouse monoclonal (8C6)
  • western blot; mouse; 1:1000; fig 1
In order to investigate MDM4 exon 6 skipping by antisense oligionucleotides and its affect on inhibiting tumor growth, EMD Millipore MDM4 antibody (Millipore, 8C6) was used in western blot on mouse samples at 1:1000 (fig 1). J Clin Invest (2016) ncbi
mouse monoclonal (QCRL-1)
  • immunocytochemistry; human; 1:25; fig 2
In order to describe methods to differentiate and characterize hPSC-derived brain microvascular endothelial cells, EMD Millipore MDM4 antibody (Millipore, QCRL1) was used in immunocytochemistry on human samples at 1:25 (fig 2). Methods (2016) ncbi
mouse monoclonal (8C6)
  • western blot; human; 1:1000; loading ...; fig 1b
EMD Millipore MDM4 antibody (Millipore, 04-1555) was used in western blot on human samples at 1:1000 (fig 1b). Oncotarget (2015) ncbi
mouse monoclonal (QCRL-1)
  • flow cytometry; human
  • immunocytochemistry; human
EMD Millipore MDM4 antibody (Millipore, MAB4100) was used in flow cytometry on human samples and in immunocytochemistry on human samples . Mol Cancer Ther (2015) ncbi
mouse monoclonal (8C6)
  • western blot; human
EMD Millipore MDM4 antibody (Millipore, 8C6) was used in western blot on human samples . Cancer Res (2014) ncbi
mouse monoclonal (8C6)
  • western blot; human; 1:1000
In order to study the role of a p53-miRNA-34 positive-feedback loop in tumor suppression in lung cancer, EMD Millipore MDM4 antibody (Millipore, 04-1555) was used in western blot on human samples at 1:1000. Genes Dev (2014) ncbi
Sigma-Aldrich
mouse monoclonal (MDMX-82)
  • western blot; human; 1:1000; fig 4
In order to investigate MDM4 exon 6 skipping by antisense oligionucleotides and its affect on inhibiting tumor growth, Sigma-Aldrich MDM4 antibody (Sigma-Aldrich, MDMX-82) was used in western blot on human samples at 1:1000 (fig 4). J Clin Invest (2016) ncbi
mouse monoclonal (MDMX-82)
  • western blot; mouse
Sigma-Aldrich MDM4 antibody (Sigma-Aldrich, MDMX82) was used in western blot on mouse samples . Cell Death Dis (2015) ncbi
mouse monoclonal (MDMX-82)
  • immunohistochemistry - paraffin section; human
  • immunoprecipitation; human; 2 ugs
  • western blot; human; fig 6
In order to study the relationship between USP2-MDM4 and p53 in tumorigenesis, Sigma-Aldrich MDM4 antibody (Sigma, M0445) was used in immunohistochemistry - paraffin section on human samples , in immunoprecipitation on human samples at 2 ugs and in western blot on human samples (fig 6). Carcinogenesis (2014) ncbi
Articles Reviewed
  1. Ng S, Yoshida N, Christie A, Ghandi M, Dharia N, Dempster J, et al. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018;9:2024 pubmed publisher
  2. Midde N, Sinha N, Lukka P, Meibohm B, Kumar S. Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells. PLoS ONE. 2017;12:e0172628 pubmed publisher
  3. Qi D, Cobrinik D. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation. Oncogene. 2017;36:1760-1769 pubmed publisher
  4. Schwermer M, Dreesmann S, Eggert A, Althoff K, Steenpass L, Schramm A, et al. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines. Clin Exp Ophthalmol. 2017;45:288-296 pubmed publisher
  5. Liu T, Xiong J, Yi S, Zhang H, Zhou S, Gu L, et al. FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2. Oncogene. 2017;36:1678-1686 pubmed publisher
  6. Riascos Bernal D, Chinnasamy P, Cao L, Dunaway C, Valenta T, Basler K, et al. β-Catenin C-terminal signals suppress p53 and are essential for artery formation. Nat Commun. 2016;7:12389 pubmed publisher
  7. Clark P, Al Ahmad A, Qian T, Zhang R, Wilson H, Weichert J, et al. Analysis of Cancer-Targeting Alkylphosphocholine Analogue Permeability Characteristics Using a Human Induced Pluripotent Stem Cell Blood-Brain Barrier Model. Mol Pharm. 2016;13:3341-9 pubmed publisher
  8. Chen S, FORRESTER W, Lahav G. Schedule-dependent interaction between anticancer treatments. Science. 2016;351:1204-8 pubmed publisher
  9. Swetzig W, Wang J, Das G. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer. Oncotarget. 2016;7:16049-69 pubmed publisher
  10. Xie X, Lozano G, Siddik Z. Heterozygous p53(V172F) mutation in cisplatin-resistant human tumor cells promotes MDM4 recruitment and decreases stability and transactivity of p53. Oncogene. 2016;35:4798-806 pubmed publisher
  11. Esfandiari A, Hawthorne T, Nakjang S, Lunec J. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner. Mol Cancer Ther. 2016;15:379-91 pubmed publisher
  12. Dewaele M, Tabaglio T, Willekens K, Bezzi M, Teo S, Low D, et al. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. J Clin Invest. 2016;126:68-84 pubmed publisher
  13. Ivanschitz L, Takahashi Y, Jollivet F, Ayrault O, Le Bras M, de Thé H. PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence. Proc Natl Acad Sci U S A. 2015;112:14278-83 pubmed publisher
  14. Stebbins M, Wilson H, Canfield S, Qian T, Palecek S, Shusta E. Differentiation and characterization of human pluripotent stem cell-derived brain microvascular endothelial cells. Methods. 2016;101:93-102 pubmed publisher
  15. Haupt S, Buckley D, Pang J, Panimaya J, Paul P, Gamell C, et al. Targeting Mdmx to treat breast cancers with wild-type p53. Cell Death Dis. 2015;6:e1821 pubmed publisher
  16. Deben C, Wouters A, Op de Beeck K, Van den Bossche J, Jacobs J, Zwaenepoel K, et al. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer. Oncotarget. 2015;6:22666-79 pubmed
  17. Pishas K, Adwal A, Neuhaus S, Clayer M, Farshid G, Staudacher A, et al. XI-006 induces potent p53-independent apoptosis in Ewing sarcoma. Sci Rep. 2015;5:11465 pubmed publisher
  18. Zhang W, Hou J, Wang X, Jiang R, Yin Y, Ji J, et al. PTPRO-mediated autophagy prevents hepatosteatosis and tumorigenesis. Oncotarget. 2015;6:9420-33 pubmed
  19. Yan H, Solozobova V, Zhang P, Armant O, Kuehl B, Brenner Weiss G, et al. p53 is active in murine stem cells and alters the transcriptome in a manner that is reminiscent of mutant p53. Cell Death Dis. 2015;6:e1662 pubmed publisher
  20. Stegeman S, Moya L, Selth L, Spurdle A, Clements J, Batra J. A genetic variant of MDM4 influences regulation by multiple microRNAs in prostate cancer. Endocr Relat Cancer. 2015;22:265-76 pubmed publisher
  21. Loganzo F, Tan X, Sung M, Jin G, Myers J, Melamud E, et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther. 2015;14:952-63 pubmed publisher
  22. Ling X, Xu C, Fan C, Zhong K, Li F, Wang X. FL118 induces p53-dependent senescence in colorectal cancer cells by promoting degradation of MdmX. Cancer Res. 2014;74:7487-97 pubmed publisher
  23. Zhuang C, Sheng C, Shin W, Wu Y, Li J, Yao J, et al. A novel drug discovery strategy: mechanistic investigation of an enantiomeric antitumor agent targeting dual p53 and NF-κB pathways. Oncotarget. 2014;5:10830-9 pubmed
  24. Jacob A, Singh R, Comiskey D, Rouhier M, Mohammad F, Bebee T, et al. Stress-induced alternative splice forms of MDM2 and MDMX modulate the p53-pathway in distinct ways. PLoS ONE. 2014;9:e104444 pubmed publisher
  25. Okada N, Lin C, Ribeiro M, Biton A, Lai G, He X, et al. A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression. Genes Dev. 2014;28:438-50 pubmed publisher
  26. Wang C, Wang J, Liu Z, Ma X, Wang X, Jin H, et al. Ubiquitin-specific protease 2a stabilizes MDM4 and facilitates the p53-mediated intrinsic apoptotic pathway in glioblastoma. Carcinogenesis. 2014;35:1500-9 pubmed publisher
  27. Qi M, Zhang J, Zeng W, Chen X. DNAJB1 stabilizes MDM2 and contributes to cancer cell proliferation in a p53-dependent manner. Biochim Biophys Acta. 2014;1839:62-9 pubmed publisher
  28. Anderson V, Walton M, Eve P, Boxall K, Antoni L, Caldwell J, et al. CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors. Cancer Res. 2011;71:463-72 pubmed publisher